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Introduction
Idiopathic pulmonary fibrosis is a rare lung disease of 
unknown origin which leads rapidly to death [1]. Epide-
miological studies suggest that the incidence of IPF has 
been increasing steadily over the last two to three dec-
ades [2]. Although the aetiology and the pathophysiology 
of IPF are still incompletely understood, two anti-fibrotic 
drugs, pirfenidone and nintedanib, have recently proven to 
be effective in slowing down disease progression and are 
now approved as treatments [3, 4]. Clinical management of 
IPF remains difficult due to a lack of accurate indicators of 
disease progression, and an absence of simple short-term 
measures of therapeutic response [5]. Although the median 
survival is about 2–3 years, there is a wide spectrum of dis-
ease courses ranging from slow evolving disease to quick 
deterioration [1].
Biological markers, often referred as biomarkers, are 
commonly defined as objectively measured elevated indi-
cators of physiological / pathological processes or phar-
macological response to therapeutic interventions [6]. Bio-
markers are highly needed in IPF as tools for differential 
diagnostic, predictor of the progression of the disease and 
treatment response [7]. Specifically in IPF, an early diag-
nostic is important to reduce as much as possible the dis-
ease progression [8, 9]. Ideally, biomarkers should easily be 
sampled and analysed for a widespread utility. Therefore, 
we focused on blood molecules or circulating cells for the 
simplicity of sampling and processing.
Abstract 
Purpose Idiopathic pulmonary fibrosis (IPF) is a progres-
sive and lethal lung disease of unknown origin whose inci-
dence has been increasing over the latest decade partly as a 
consequence of population ageing. New anti-fibrotic ther-
apy including pirfenidone and nintedanib have now proven 
efficacy in slowing down the disease. Nevertheless, diagno-
sis and follow-up of IPF remain challenging.
Methods This review examines the recent literature on 
potentially useful blood molecular and cellular biomark-
ers in IPF. Most of the proposed biomarkers belong to 
chemokines (IL-8, CCL18), proteases (MMP-1 and MMP-
7), and growth factors (IGBPs) families. Circulating T 
cells and fibrocytes have also gained recent interest in that 
respect. Up to now, though several interesting candidates 
are profiling there has not been a single biomarker, which 
proved to be specific of the disease and predictive of the 
evolution (decline of pulmonary function test values, risk 
of acute exacerbation or mortality).
Conclusion Large scale multicentric studies are eagerly 
needed to confirm the utility of these biomarkers.
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IPF Definition and Diagnostic Criteria
IPF is defined as a chronic progressive fibrosing interstitial 
pneumonia of unknown origin [1]. The disease is limited to 
the lung and associated to a typical radiologic (subpleural 
and basal predominance, reticulations, honey combing with 
or without bronchiectasis and no atypical images) and his-
topathologic pattern (marked fibrosis with architectural dis-
tortion, subpleural, patchy involvement of lung, fibroblast 
foci, absence of inconsistent features) [1]. The diagnosis of 
IPF also requires the exclusion of other forms of intersti-
tial pneumonia including other idiopathic interstitial lung 
diseases and ILD’s associated to systemic disease, environ-
mental, exposure or medication. In particular, it is impor-
tant to exclude chronic hypersensitivity pneumonitis as a 
hidden cause of IPF by measuring specific IgG [10]. The 
exploration can be continued by performing a bronchos-
copy (with bronchoalveolar lavage), a pulmonary biopsy or 
a cryobiopsy. All cases have to be discussed by a multidis-
ciplinary group composed of a pulmonologist, a specialist 
in pulmonary rehabilitation, a rheumatologist, a radiologist, 
a pathologist and a specialist in occupational medicine.
Biomarkers (Table 1)
Here we have performed a systematic search in pubmed 
by typing the words “biomarkers” and “IPF” and select-
ing those measured in blood. Publications dates of selected 
papers range from 1993 until 2016.
Many biomarkers have been studied in BALF and in 
serum as potential diagnostic or prognostic tools. Their 
utility for monitoring the disease has to be assessed [11].
Alveolar Epithelial Markers
The main biomarkers associated with the alveolar epithe-
lial cell damage (or dysfunction) are the Krebs von den 
Lungen-6 (KL-6) antigen and the surfactant protein A and 
D (SP-A and SP-D). Compared to SP-A and SP-D, serum 
KL-6 has a highest accuracy for diagnosis of interstitial 
lung diseases (IPF and ILD associated with connective tis-
sue diseases) [11].
Krebs von den Lungen‑6 Antigen (KL‑6)
KL-6 is a high molecular weight glycoprotein classified as 
a human transmembrane mucin 1 (MUC1). That glycopro-
tein is mainly expressed at the extracellular membrane sur-
face of type II pneumocytes [12–14]. It has been initially 
studied in non-IPF interstitial lung diseases (ILDs) and 
appeared to be also elevated in IPF with a possible correla-
tion with an increased risk of IPF associated mortality [14, 
15]. KL-6 promotes migration, proliferation and survival of 
lung fibroblasts [16, 17] and therefore is possibly involved 
in the IPF pathophysiological process. A serum baseline 
level above 1000 U/ml seems to be associated with a worse 
outcome [18, 19]. Our data indicate that serum KL-6 levels 
are markedly increased in IPF as compared to healthy sub-
jects but we did not find reduced KL-6 levels in the patients 
treated by pirfenidone or nintedanib [20]. Serum KL-6 
could possibly be associated to treatment response but this 
needs further longitudinal studies to be confirmed.
Surfactant Protein A and D (SP‑A and SP‑D)
Surfactant proteins are lipoprotein complexes synthesized 
and secreted by type II pneumocytes to decrease surface 
tension at the air–liquid interface. They have also a role in 
the lung host defence. Serum SP-A and SP-D are known as 
being elevated in patients with ILD with a greater extend 
in IPF [21–25]. Some findings also suggest that surfactant 
lipids may protect against intraluminal fibrogenesis by 
inducing fibroblast apoptosis and decreasing collagen accu-
mulation [26]. In this context, SP-A and SP-D have been 
shown to be predictive of survival when assessed at the ini-
tial work up of the disease [24, 27]. Their involvement in 
the IPF physiopathological process is underlined by famil-
ial form of IPF associated with mutations of surfactant pro-
tein C [28].
Fibrogenesis and Extracellular Remodelling Markers
The main biomarkers identified in IPF focusing on fibro-
genesis are matrix metalloproteinases (MMP)-1 and -7, 
Lysyl oxidase-like 2 (LOXL2) and Periostin.
Matrix Metalloproteinases‑1 and ‑7 (MMP‑1 and MMP‑7)
Matrix metalloproteinases are a collection of zinc-depend-
ent proteases involved in the breakdown and the remodel-
ling of extracellular matrix components [29]. MMP-1 and 
MMP-7 seem to be primarily overexpressed in plasma of 
IPF patients compared to hypersensitivity pneumonitis, 
sarcoidosis and COPD with a possible usefulness in differ-
ential diagnosis [30]. They are also involved in inflamma-
tion and seem to take part to the pathophysiological process 
of pulmonary fibrosis [31, 32]. The most studied is clearly 
MMP-7 which is known as being significantly increased in 
epithelial cells both at the gene and protein levels and is 
considered to be active in hyperplastic epithelial cells and 
alveolar macrophages in IPF [33]. There is also a signifi-
cant correlation between higher MMP-7 concentrations and 
disease severity assessed by forced vital capacity (FVC) 
and DLCO (%pred) [30]. We therefore can identify MMP-7 
as one of the greatest individual biomarkers in IPF.
Lung 
1 3
Concentrations of protein fragments generated by 
MMP activity are increased in the serum of individu-
als with IPF compared with healthy controls. Increased 
neoepitope concentrations were associated with disease 
progression as defined by death or decline in FVC > 10% 
at 12  months after study enrolment and the rate of this 
increase predicted survival [5, 34]. We can hypothesize 
that as neoepitopes are generated by proteases they could 
be associated with lung remodelling and fibrotic process.
Lysyl Oxidase‑like 2 and Periostin
Lysyl oxidase-like 2 (LOXL2) is expressed in fibrotic lung 
and is thought to play a crucial role in matrix remodelling 
and fibrogenesis [35]. Serum level of LOXL2 is correlated 
Table 1  Summary of main potential serum biomarkers in IPF
KL‑6 Krebs von den lungen-6 antigen, SP‑A Surfactant protein A, SP‑D Surfactant protein D, MMP‑1 Matrix metalloproteinase-1, MMP‑7 
Matrix metalloproteinase-7, LOXL2 lysyl oxidase-like 2, CCL18 CC chemokine ligand 18, IL‑8 interleukin-8, IGFBP‑2 insulin-like growth fac-
tor binding protein-2, HSP70 Heat shock protein 70, CXCL‑13 C-X-C motif chemokine 13
Biomarker Diagnostic Prognosis Protein level in blood Ref
Alveolar epithelial markers KL-6 + + Serum baseline level > 1000 U/ml is 
associated with worse prognosis and 
>1300 U/ml with increased risk of acute 
exacerbation
[14, 74]
SP-A and SP-D + + Increase of 49 ng/mL (1 SD) in baseline 
SP-A level was associated with a 3.3-
fold increased risk of mortality n the 
first year after presentation. SP-A and 
SP-D are predictors of worse survival in 
one year mortality regression model
[24, 25]
Fibrogenesis& extracellular remodelling MMP-1 & MMP-7 + + Higher levels associated to disease pro-
gression and worse survival (>4.3 ng/ml 
for MMP-7)
[30]
LOXL2 − + Higher levels associated with increased 
risk of progression (>700 pg/ml)
[36]
Periostin − + Increase level of 116.97 μg/ml levels is 
associated with disease progression
[39]
ECM-neoepitope − + Changes in levels are associated with 
disease progression
[34]
Chemokines CCL18 − + Baseline concentration > 150 ng/ml asso-
ciated with higher mortality
[44]
IL-8 + + Higher levels associated with worse prog-
nosis (>7.2 pg/ml)
[46, 47]
Growth factors & Adhesion molecules YKL-40 − + High levels (>79 ng/ml) associated with a 
worse prognosis
[51]
IGFBP-2 + Not known Higher level in IPF reduced in patients 
with specific anti-fibrotic therapy
[20]
ICAM-1 − + High level associated with worse progno-
sis (>202.5 ng/ml)
[48, 53]
VEGF − + Higher levels associated with the disease 
severity and to predict decline in pulmo-
nary function tests (207 pg/ml)
[56]
Others HSP70 − + The presence of anti-HSP70 IgG is associ-
ated with an increase morbi-mortality
[58, 75, 76]
Leptin − + Worse survival when >13.79 ng/ml in 
case of acute exacerbation
[60]
CXCL13 + + Higher levels is associated with a worse 
prognosis
[67, 77]
Circulating cells T-cells (Sema7a
/CD28)
+/− + Reduce expression of CD28 or increase 
Sema7a + Treg is associated with a 
higher mortality
[62, 65, 78]
Fibrocytes − + Elevated circulating fibrocytes (>5%) is 




to IPF disease progression (assessed by classical regres-
sion tree method) [36]. Nevertheless, anti-LOXL2 targeted 
therapy trial failed to reduce IPF disease progression [37]. 
Periostin, an extracellular matrix protein that contributes 
to fibrosis in the lung, is highly elevated in blood of IPF 
patients as well as in lung tissue [38]. In lung tissue, it is 
specifically found in the “fibroblast foci”, typically seen in 
IPF. Plasma level of periostin is also correlated with a com-
posite score reflecting disease progression [39].
Chemokines
CC Chemokine Ligand 18
CC motif chemokine ligand 18 (CCL18) is a small protein 
derived from alveolar macrophages that acts as a chemo-
attractant. CCL18 is mainly secreted by antigen-presenting 
cells such as monocytes, macrophages and dendritic cells 
[40]. In the setting of pulmonary fibrosis, alveolar mac-
rophages are believed to be the main source of CCL18 in 
the lung and play a role in the pathogenesis of pulmonary 
fibrosis [41]. Serum CCL18 is increased in IPF but is not 
specific of the disease [41–43]. In IPF, CCL18 is nega-
tively correlated to pulmonary function tests (TLC and 
DLCO) [42]. In a prospective study, it has been shown that 
patients with serum level of CCL18 > 150 ng/ml were inde-
pendently associated with death in IPF (HR 1.98, 95% CI 
2.49–25.51, p = 0.005) [44]. Moreover, pirfenidone one of 
the specific anti-fibrotic therapies in IPF significantly sup-
pressed the expression of CCL18 on macrophages [45]. 
Therefore, CCL18 could have a potential interest as a prog-
nostic tool in IPF.
Interleukin‑8 (IL‑8)
IL-8 is a cytokine, which is highly chemo-attractant for 
neutrophils and known to be elevated in serum of IPF 
patients. A study identified a negative correlation between 
IL-8 and pulmonary function tests (DLCO, TLC, VC) [46, 
47] and survival [48] underlying its potential utility as bio-
marker in IPF.
Growth Factors and Adhesion Molecules
YKL‑40
YKL-40 is a chitinase-like protein that regulates cell pro-
liferation and survival and has previously been described 
in liver fibrosis. YKL-40 has also been well studied in 
multiple ILDs [13]. Its mechanism of action is not under-
stood yet but seems to be associated with a promitogenic 
action on lung fibroblasts in animal model and increases 
macrophages activity in COPD [49, 50]. Moreover, 
YKL-40 has been found to be increase in fibrotic areas of 
IPF patients and especially in macrophages and bronchial 
cells [13]. In a prospective study, YKL-40 is not specific 
for IPF but a serum level above 79 ng/ml is associated with 
a worse prognosis (HR 10.9, 95% CI 1.9–63.8, p < 0.01) 
[51]. Therefore, we think that YKL-40 is useful at diagno-
sis for prognosis stadification and could be considered.
Insulin‑like Growth Factor 2 (IGFBP‑2)
IGFBP-2 is a member of a highly conserved family of six 
insulin-like growth factor (IGF) binding proteins, which 
has recently been identified in IPF [20, 52]. IGF and 
IGFBPs are described to be involved in cell proliferation 
and differentiation. In a cross sectional study on 50 patients 
suffering from IPF, we have recently shown that IGFBP-1 
and IGFBP-2 are increased in newly diagnosed IPF and 
IGFBP-2 reduced in patients treated with anti-fibrotic 
therapy though still raised as compared to healthy subjects 
[20]. However, we did not report any correlation between 
IGFBP-2 and impaired lung function indices. In contrast 
to IGFPB-1 and -2, it turned out that IGF-1 and -2 were 
decreased in serum of untreated IPF. Further, longitudinal 
studies are needed to evaluate their usefulness as biomark-
ers in IPF.
ICAM‑1 and ICAM‑2
Intracellular adhesion molecule-1 and -2 (ICAM-1 and 
ICAM-2) are also elevated (not specifically) in serum from 
patient with IPF. ICAM-1 has been found to be overex-
pressed on pulmonary epithelial cells of patients with IPF 
[53, 54], whereas ICAM-2 has been inversely associated 
with DLCO. Its utility in clinical practice is not yet known 
and has to be explored in longitudinal studies.
VEGF
Vascular endothelial growth factor (VEGF) is a glycopro-
tein expressed in alveolar epithelial cells [55]. Increased 
serum VEGF, but not CRP, has been identified in one lon-
gitudinal study of 41 IPF patients and potentially associated 
with the disease severity as reflected by the alveolo-arterial 
difference of  O2. In this study, serum levels of VEGF in 
severely hypoxemic IPF were similar to those found in non-
small cell lung carcinoma [56]. Serum VEGF was associ-
ated with increased loss in VC over time. Survival rate at 
5 years was decreased in patients whose VEGF level was 
above 207  pg/ml. Of interest, VEGF is targeted by nint-




The heat shock protein 70 (HSP 70) is a molecular chap-
erone that is expressed in response to stress. IgG autoan-
tibodies directed to HSP70 have been associated with a 
poorer prognostic in IPF [58]. In addition, Fibulin-1 is 
elevated in IPF and correlated with the disease progres-
sion [59]. Plasma leptin level, a biomarker traditionally 
associated with obesity, is also significantly increased in 
case of acute exacerbation of IPF. In one longitudinal study 
of 61 IPF patients, those patients with plasma leptin lev-
els > 13.79 ng/ml at hospital admission had increased mor-
tality [60].
A recent study focusing on biomarkers that might assist 
in distinguishing IPF from non-IPF-ILDs have identify in 
the plasma of 149 IPF patients (derivation cohort n = 86, 
validation cohort n = 63) that a biomarker index composed 
of SP-D, MMP-7 and osteopontin enhanced diagnos-
tic accuracy for IPF compared to other ILDs (rheumatoid 
arthritis associated ILD (n = 33); alternative idiopathic ILD 
(n = 41)) [61]. This three analyte panel of SP-D, MMP-7 
and osteopontin enhance the odds of IPF diagnosis when 
each of them exceed its threshold value (>31  ng/ml, 
>1.75 ng/ml and >6 ng/ml, respectively) [61].
Circulating Cells
T-cells are also involved in the pathophysiology of IPF. 
Semaphorin 7a (Sema 7a), a membrane-bound protein 
expressed in activated Tcells, also regulates inflammatory 
responses via stimulation of macrophage chemotaxis and 
cytokine production chemokine expression, modulation of 
T-cell function and regulation of collagen production by 
fibrocytes. Hematopoietic expression of Sema 7a is suf-
ficient to induce fibrosis in TGF-β1–induced murine lung 
fibrosis [62]. There is an increased expression of  Sema7a+ 
on T-regulatory cells in IPF [62–64]. Its protective or del-
eterious impact in IPF is not known yet. By contrast, CD28 
(a marker of T-cell activation) is less expressed in IPF with 
a higher incidence of mortality in case of low expression 
[65]. As it has been shown in several auto-immune dis-
ease, there is a lower expression of  CD4+CD25+FOXP3+ 
T reg cells in IPF [66]. Other teams have been focusing on 
B-cell activation using BLys (B-cell activating factor) and 
CXCL13, which underlined the potential implication of 
B-cells in IPF [67].
Circulating  CD45+Col-1+ fibrocytes are circulating 
bone-marrow derived mesenchymal progenitor cells which 
can differentiate into fibroblast and myofibroblasts [68]. 
They are increased in IPF compared to healthy subjects. 
Their circulating level in IPF (>5% of total blood leuko-
cytes) is associated with a worse survival [69, 70].
Further Approach
Genomic, epigenetic and molecular phenotyping are widely 
used in clinical research. It is getting more and more clear 
that genetic polymorphisms, whole blood transcriptomic 
profile, as well as lung microbiome are predicting groups of 
diverse disease behaviour and response to treatment [71]. 
Extracellular vesicles containing micro-RNA are known 
to express surface protein and hold nucleic acid, including 
microRNAs, and to regulate gene expression in the recipi-
ent cells. A recent study identified miR-21-5-p as to be ele-
vated in the serum of IPF and associated to the disease pro-
gression and the overall prognosis [72]. Many other miR 
have also been identified like miR-7, miR-29 and miR-125b 
[73].
Limitations
One of the limitations of our review is that we have cho-
sen candidate biomarkers in IPF according to our thinking 
and their potential usefulness. Another limitation is the lack 
of longitudinal studies for some of the biomarkers, which 
reduces the clinical impact of the finding because of a lack 
of assessment of treatment response. We believe that fur-
ther longitudinal multicentre studies are highly needed to 
evaluate the real clinical impact of most of the biomarkers 
in a single or multivariate analysis as diagnostic and prog-
nostic tools.
Conclusion
Diagnosis of IPF remains challenging and requires a multi-
disciplinary approach. Treatments currently available have 
a limited efficacy and the overall prognosis of the disease 
remains poor. Recent advance in pathophysiological pro-
cess are promising for further therapies; nevertheless, the 
most important point for now is the early diagnosis as a 
mean to early treatment. So far, there is no easy to use bio-
marker available for clinical practice. It is now obviously 
clear that genetic and epigenetic variations are involved 
in the pathogenesis giving us different information for the 
morbi-mortality in IPF. Furthermore, prospective longitu-
dinal studies have started to identify blood biomarkers to be 
used in clinical practice.
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